Last reviewed · How we verify
NCT03941652: eMOMGDM
Usability Study of the Sensors and eMOM GDM Application
trial in Gestational Diabetes in 54 participants. Participants enrolled and being followed up; not accepting new ones.
30 October 2022
Quick facts
| Lead sponsor | Helsinki University Central Hospital |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 54 |
| Start date | 27 May 2019 |
| Primary completion | 30 October 2022 |
| Estimated completion | 30 December 2026 |
| Sites | 1 location across Finland |
Conditions studied
- Gestational Diabetes — all drugs for Gestational Diabetes →
Sponsor
Helsinki University Central Hospital
Who can join
Adults 18 to 68, female only, with Gestational Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The principal aim of the eMOM GDM-project is to evaluate the effect of the eMOM GDM -application and the integrated service concept model on maternal and neonatal outcomes. In the first phase of the project the investigators evaluate the usability, functionality and acceptability of developed eMOM GDM application and used sensors (continuous glucose meter, accelerometer, speech-enabled food record, optical pulse, beat-to-beat heart rate). Two different user interfaces (one for the women with GDM and one for the health care professionals) of the eMOM GDM application will we be developed and evaluated.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03941652
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gestational Diabetes
Currently open trials in the same condition.
- NCT07171684 — Single vs Multi-Dose Insulin for Glycemic Control (SUGAR) · NA · recruiting
- NCT07314944 — Maternal Sleep and Lifestyle, Metabolic Health, and Perinatal Outcomes in Gestational Diabetes · recruiting
- NCT06571487 — Growth Hormone Resistance of Beta-cells · recruiting
- NCT07336914 — Effect of Conventional vs Intensive Management on Gestational Diabetes and Maternal Fetal Outcomes · NA · recruiting
- NCT07174245 — Pregnancy and Postpartum CGM in GDM · recruiting
Other Helsinki University Central Hospital trials
Trials by the same sponsor.
- NCT07423637 — The Impact of Early Automated Insulin Delivery (AID) Therapy on Diabetes Control and Comorbidities, and Cost-effectivene · NA · not yet recruiting
- NCT07462559 — KF2025#1 Trial: Ketamine, Cannabidiol and Cobicistat Interaction Study · Phase 1 · not yet recruiting
- NCT07458984 — FMT Capsules for rCDI · Phase 3 · not yet recruiting
- NCT07001423 — ChOlecystectomy aFter successFul Endoscopic Common Bile Duct Stone Extraction in Elderly · NA · recruiting
- NCT07155629 — Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03941652 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Helsinki University Central Hospital
- Last refreshed: 11 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03941652.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing